Find, compare & contact
Histrelin
API Manufacturers & Suppliers
United States
India
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Histrelin API 76712-82-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Histrelin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Histrelin
- Synonyms:
- histrelina , histreline , histrelinum
- Cas Number:
- 76712-82-8
- DrugBank number:
- DB06788
- Unique Ingredient Identifier:
- H50H3S3W74
About Histrelin
Do you want to know more about Histrelin? You can find a small explanation about it here. Histrelin is a gonadotropin releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant that delivers continuous therapeutic doses. Following an initial stimulatory phase with increased circulating levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient increase in concentration of gonadal steroids (testosterone and dihydrotestosterone in males), continuous administration of histrelin acetate results in decreased levels of LH and FSH due to a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes.
Check who is selling Histrelin in the overview above.
Histrelin is a type of Gonadorelin agonists
Gonadorelin agonists belong to the subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in reproductive medicine. These compounds are designed to mimic the activity of gonadotropin-releasing hormone (GnRH), a hormone responsible for the regulation of reproductive function.
Gonadorelin agonists work by binding to and activating GnRH receptors in the pituitary gland. This results in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are essential for the normal functioning of the reproductive system.
These pharmaceutical agents have a wide range of applications, primarily in the field of assisted reproductive technology (ART) and hormone-related disorders. They are commonly used in the treatment of infertility, endometriosis, and precocious puberty. In ART, gonadorelin agonists are employed to stimulate the ovaries and induce ovulation, increasing the chances of successful conception during in vitro fertilization (IVF) procedures.
Gonadorelin agonists are available in different formulations, including injectables and nasal sprays, allowing for flexible administration based on individual patient needs. They are generally well-tolerated, with common side effects including headache, hot flashes, and mild injection site reactions.
Overall, gonadorelin agonists are critical components in the field of reproductive medicine, assisting in the management of various fertility-related conditions. With their targeted action on the GnRH receptors, these pharmaceutical APIs continue to contribute to advancements in assisted reproduction and the overall well-being of patients.
Histrelin (Gonadorelin agonists), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
